75 Quick summary: Belgian researchers have discovered a molecular pathway that allows cancer cells to withstand therapeutic pressure by directly connecting lipid metabolism to the regulation of crucial tumour suppressor proteins. By demonstrating that the interaction of a specific metabolic enzyme with an epigenetic regulator protects aggressive breast and colorectal tumours from oxidative stress, the preclinical study reveals a major mechanism behind treatment resistance. For healthcare practice and public policy, translating these findings into combined targeted therapies offers a promising new frontier towards overcoming treatment failure, reducing patient relapse rates, and improving long-term survival outcomes. Researchers in Belgium have identified a molecular pathway that helps cancer cells withstand treatment by connecting lipid metabolism to the regulation of key tumour suppressor proteins. A research team from the Cancer Metabolism and Tumour Microenvironment Laboratory at the University of Liège has uncovered a previously unrecognised mechanism that promotes cancer cell survival under therapeutic pressure. Published in MedComm on 11th June 2026, the study shows how a key enzyme in lipid metabolism, stearoyl-CoA desaturase 1 (SCD1), cooperates with an epigenetic regulator to support tumour growth. Led by Professor Nor Eddine Sounni, the team investigated how cancer cells adapt to hostile conditions such as hypoxia, nutrient deprivation, and exposure to anticancer therapies. These cells reprogramme their metabolism, particularly lipid metabolism, to sustain proliferation. While SCD1 has long been associated with aggressive tumour behaviour, the precise molecular mechanisms underlying its role in therapy resistance remained poorly understood. The researchers discovered that SCD1 physically interacts with HDAC2, a major regulator of gene expression and protein activity. This interaction promotes the deacetylation of nucleophosmin 1 (NPM1), a multifunctional protein involved in cellular stress responses and in the regulation of the tumour suppressor p53 pathway. The resulting SCD1/HDAC2/NPM1 axis enhances cancer cell survival under oxidative stress and promotes tumour growth. “Our work reveals an unexpected link between lipid metabolism and the post-translational regulation of a tumour-suppressor-related pathway,” said Professor Sounni. “This discovery provides new insight into how tumour cells adapt to stress and highlights a promising combined therapeutic strategy.” To validate their findings, the researchers used breast and colorectal cancer cell lines as well as mouse models. They demonstrated that inhibition of SCD1 sensitises cancer cells to HDAC inhibitors, agents already used in oncology, and that the combination produced a synergistic antitumour effect. Cancer cells routinely rewire their energy production and building-block synthesis to fuel rapid growth and survive in the low-oxygen environments common within solid tumours. SCD1, which converts saturated fatty acids into monounsaturated ones, supports the formation of lipid droplets that protect cells from oxidative damage. In this study, the physical interaction between SCD1 and HDAC2 was shown to influence NPM1 acetylation status, affecting its localisation and function and allowing cancer cells to manage stress and evade therapies designed to trigger cell death. The work builds on earlier research from the same laboratory linking SCD1 to tumour progression and resistance to ferroptosis, a form of iron-dependent cell death. By connecting lipid desaturation directly to epigenetic control, the new findings expand understanding of how metabolism and gene regulation intersect in oncology. Preclinical data from mouse models indicated reduced tumour growth when SCD1 inhibition was combined with existing HDAC inhibitors, suggesting improved outcomes without relying solely on higher doses of single agents. The pathway was observed in models of breast and colorectal cancers, and given that many solid tumours exhibit similar metabolic adaptations, targeting this axis may have relevance across multiple cancer types. Professor Sounni’s group collaborated with platforms at the GIGA Institute, including Cell Imaging and Flow Cytometry, to conduct detailed molecular and in-vivo analyses. The study was supported by Belgian funding bodies and published open access in MedComm. While the research remains at the preclinical stage, experts note that metabolic vulnerabilities represent an emerging frontier in cancer therapy, and that disrupting the systems cancer cells rely on for adaptation may help overcome resistance, a major cause of treatment failure and relapse. The findings provide a strong rationale for further development of SCD1-targeted compounds in combination-regimen approaches, though clinical translation will require careful assessment of safety and efficacy in patients with advanced or resistant disease.